Synthetic surfactant could ease breathing for patients with lung disease and injury

July 9, 2018, Lawson Health Research Institute
Dr. Ruud Veldhuizen, scientist at Lawson Health Research Institute and co-investigator on the study. Credit: Lawson Health Research Institute

Human lungs are coated with a substance called surfactant which allows us to breathe easily. When lung surfactant is missing or depleted, which can happen with premature birth or lung injury, breathing becomes difficult. In a collaborative study between Lawson Health Research Institute and Stanford University, scientists have developed and tested a new synthetic surfactant that could lead to improved treatments for lung disease and injury.

Lung surfactant is made up of lipids and proteins which help lower tension on the 's surface, reducing the amount of effort needed to take a breath. The proteins, called surfactant-associated proteins, are very difficult to create in a laboratory and so the surfactant most commonly used in medicine is obtained from animal lungs.

London, Ontario has a rich legacy in surfactant research and innovation. Dr. Fred Possmayer, a scientist at Lawson and Western University, pioneered the technique used to purify and sterilize lung surfactant extracted from cows. Called bovine lipid extract surfactant (BLES), the therapeutic is made in London, Ontario and used by nearly all neonatal intensive care units in Canada to treat premature babies with respiratory distress.

"When we look at treating adults, surfactant therapy is more difficult. For example, their lungs are 20 times bigger than those of babies and so we need much higher doses of surfactant," explains Dr. Ruud Veldhuizen, a scientist at Lawson and an associate professor at Western University's Schulich School of Medicine & Dentistry. "We therefore need to find novel approaches to surfactant therapy for adult patients."

In this collaborative study, the research team took a new approach to creating synthetic surfactant. Rather than trying to recreate surfactant-associated proteins in the lab, scientists at Stanford created mimics. Pioneered by Dr. Annelise Barron, associate professor at Stanford, these protein mimics look like surfactant-associated proteins and have similar properties but are easier to create and more stable. As a result, the team was able to create a new synthetic surfactant.

Collaborating with the Stanford team, Dr. Veldhuizen evaluated the synthetic surfactant in animal models in his research lab at St. Joseph's Health Care London. The study showed that, unlike other synthetic surfactants currently on the market, the new surfactant equaled or outperformed the animal-derived surfactant in every outcome. This included outperforming animal-derived surfactant in oxygenating blood, which is the lungs' main purpose.

"The unique ability of the Veldhuizen lab to perform these rigorous and sophisticated studies was a critical aspect of the success of this project," says Dr. Barron.

"These are very promising results," says Dr. Veldhuizen. "For the first time, a synthetic surfactant has been developed which appears to be just as effective, if not more so, as that taken from the lungs of animals."

The team estimates that the synthetic surfactant could be produced at as low as one quarter of the cost of the animal-derived surfactant. With a lower cost the synthetic surfactant could be tested with more lung diseases and injuries in adults and made available in more developing countries.

The team hopes to continue their research with further testing of the synthetic surfactant, including its long term effects. The team also hopes to test its ability to be customized for specific diseases. "Since it is made in the lab, we could combine the surfactant with other drugs like antibacterial agents and deliver it to specific areas of the lung, such as those where an infection is located," explains Dr. Veldhuizen.

One disease the scientists would like to further study is acute respiratory distress syndrome (ARDS). ARDS is characterized by a low amount of oxygen in the blood due to difficulty breathing. While current surfactants have been tested with ARDS patients, they have not been effective. Dr. Veldhuizen wants to combine this new synthetic surfactant with anti-inflammatory agents and antibacterial agents to test whether patient outcomes are improved.

The study, "Effective in vivo treatment of acute with helical, amphipathic peptoid mimics of pulmonary proteins," is published in Scientific Reports.

Explore further: Scientist develops protein mimic to help injured lungs breathe

More information: Ann M. Czyzewski et al, Effective in vivo treatment of acute lung injury with helical, amphipathic peptoid mimics of pulmonary surfactant proteins, Scientific Reports (2018). DOI: 10.1038/s41598-018-25009-3

Related Stories

Scientist develops protein mimic to help injured lungs breathe

April 30, 2018
The material could be used to synthesize a film that coats the inner surface of lungs, possibly leading to better, cheaper treatments for acute lung injury in humans.

Vaping less harmful to lung fluids than smoking, study shows

January 26, 2018
A new Ohio University engineering study shows that e-cigarettes, while still toxic, are less harmful than conventional cigarettes.

Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome

March 7, 2012
Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.

Late surfactant does not cut duration of ventilation in BPD

March 1, 2016
(HealthDay)—Late administration of surfactant does not reduce the duration of ventilation in very preterm neonates with prolonged respiratory distress, according to research published online Feb. 29 in JAMA Pediatrics.

Gene therapy to correct surfactant protein B deficiency in newborns

July 26, 2017
An article published in Experimental Biology and Medicine (Volume 242, Issue 13, July, 2017) reports that gene therapy may be used to as an intermediate therapy for newborns with surfactant protein deficiencies until lung ...

Recommended for you

Enzyme identified as possible novel drug target for sickle cell disease, Thalassemia

July 19, 2018
Medical researchers have identified a key signaling protein that regulates hemoglobin production in red blood cells, offering a possible target for a future innovative drug to treat sickle cell disease (SCD). Experiments ...

Mice given metabolite succinate found to lose weight by turning up the heat

July 19, 2018
A team of researchers with members from institutions across the U.S. and Canada has found that giving the metabolite succinate to mice fed a high-fat diet prevented obesity. In their paper published in the journal Nature, ...

Supplement may ease the pain of sickle cell disease

July 19, 2018
(HealthDay)—An FDA-approved supplement reduces episodes of severe pain in people with sickle cell disease, a new clinical trial shows.

Scientists uncover DNA 'shield' with crucial roles in normal cell division

July 18, 2018
Scientists have made a major discovery about how cells repair broken strands of DNA that could have huge implications for the treatment of cancer.

Researchers develop novel bioengineering technique for personalized bone grafts

July 18, 2018
Scientists from the New York Stem Cell Foundation (NYSCF) Research Institute have developed a new bone engineering technique called Segmental Additive Tissue Engineering (SATE). The technique, described in a paper published ...

Researchers report protein kinase as the switch controlling obesity and diabetes

July 18, 2018
One of the research lines targeting the worldwide obesity epidemic is the manipulation of brown adipose tissue, a 'good' type of fat that burns lipids to maintain an appropriate body temperature. Researchers at the Centro ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Anonym239127
not rated yet Jul 19, 2018
There has been little if any progress in finding a cure or reliable treatment. So this year his primary physician suggested we started him on Natural Herbal Gardens Idiopathic Pulmonary Fibrosis Herbal formula which eased his anxiety a bit,, We ordered their IPF herbal treatment after reading alot of positive reviews, i am happy to report with the help of Natural Herbal Garden natural herbs we have been able to reverse my husband symptoms using herbs, his symptoms totally declined over a 9 weeks use of the Natural Herbal Gardens IPF natural herbal formula. His Idiopathic pulmonary fibrosis is totally reversed! Their official web page is www . naturalherbalgardens . com After the herbal treatment he also finally was able to give up smoking after 20 years. We are thankful to nature, herbs are truly gift from God

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.